DBV Technologies S.A. (DBVT): Revenue
$5.64M
Year ended 2025-12-31
+5.2%
3-year compound annual growth
-13.0%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.64M | +35.8% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $4.15M | -73.6% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $15.73M | +224.7% | 2025-04-11, From 2023-01-01 |
| 2022-12-31 | $4.84M | -15.1% | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | $5.71M | -49.4% | 2023-03-02, From 2021-01-01 |
| 2020-12-31 | $11.28M | -23.3% | 2022-03-09, From 2020-01-01 |
| 2019-12-31 | $14.71M | n/a | 2021-03-17, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $5.64M | +35.8% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $5.20M | +12.5% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $6.65M | -51.2% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $4.63M | +55.3% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $4.41M | +8.8% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $4.04M | +254.7% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $3.51M | -90.6% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $3.48M | -67.4% |
| Curis Inc (CRIS) | 2025-12-31 | $9.44M | -13.4% |
Compare DBVT, ZEOX, FATE, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗